Impact of Remote Care in Patients Diagnosed With Thromboembolic Disease of Low Risk (TEVEDOM)

Centre Hospitalier Eure-Seine

Status

Enrolling

Conditions

Thromboembolic Disease

Treatments

Other: 4G tablet

Study type

Interventional

Funder types

Other

Identifiers

NCT05684770

CHES N°22/02 (Other Identifier)

2022-A00894-39

Details and patient eligibility

About

The goal of this clinical trial is to learn about the feasibility and impact of remote care in patients diagnosed with thromboembolic disease of low risk. The main questions it aims to answer are:

the evaluation of feasibility of organisation between different healthcare professionals (hospital physicians, primary care physician) at 6 months and 1 year
the evaluation of complication rate, hospitalisation related to thromboembolic disease rate, compliance to treatment rate at 6 months and 1 year Participants will receive indication of treatment according to national recommendations. Additionnally, they will receive for the length of study a 4G tablet in order to fill questionnaires, learn information about their drugs (patient education), have a remote consultation and evaluate treatment compliance.

Enrollment

50 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

patients identified in the emergency department with a thromboembolic disease, with a deep vein thrombosis or pulmonary embolism with a low risk of mortality according to recommendations
affiliated or beneficiary of social protection

Exclusion criteria

patient having a severe obstruction syndrome, a thromboembolic disease already under treatment or a suspicion of thrombocytopenia induced by heparin
patient with an active hemorrhage or a major risk of hemorrhage, a renal severe failure, comorbidities such as cancer, or the impossibility to organise a consultation or a patient in a non favorable medico-social context
patient with a caval thrombosis
patient suffering of a disease at hemorrhagic risk or neurosurgery intervention done in the last month or other surgery in the last 15 days prior to inclusion
patient with contraindication of direct oral anticoagulants, such as bitherapy with antiplatelet agent, imidazoles, macrolides, antiretroviral treatments or an anti-phospholipid syndrome
patient that lives in an area not covered by internet
patient that has no primary care physician
patient not able to understand the study (language, psychological problem) or not able to read or write
patient under legal protection